Nintedanib Zentiva Pharma (Nintedanib Esylate)

Nintedanib, the active ingredient in Nintedanib Zentiva Pharma, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination with chemotherapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Zentiva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Nintedanib targets fibrotic lung disease pathways and certain oncologic indications. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination with chemotherapy): enhances treatment efficacy and may extend survival.

Nintedanib may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Diarrhea: frequent loose stools, often early in treatment. - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes. - Decreased appetite: reduced desire to eat. Serious or Rare Side Effects: - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Bleeding events: gastrointestinal or other hemorrhage. - Cardiovascular events: arterial thrombotic episodes.

When prescribing Nintedanib, clinicians should consider several precautionary measures to minimize risk. - Monitor liver function: check ALT, AST, bilirubin before and during therapy. - Assess bleeding risk: avoid in patients with active ulcers or anticoagulant overuse. - Evaluate cardiovascular status: caution in patients with recent arterial thrombotic events. - Watch for gastrointestinal complications: manage diarrhea and nausea promptly. - Pregnancy and lactation: avoid use; insufficient data, discuss risks with healthcare provider. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nintedanib can interact with other medicines, affecting its safety or effectiveness. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure, risk of toxicity. - Anticoagulants (e.g., warfarin): heightened bleeding risk. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors or inducers: may alter plasma levels, require monitoring. - P-glycoprotein substrates: potential changes in absorption. - Concomitant NSAIDs: may increase gastrointestinal bleeding risk.